Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Transfus Apher Sci. 2021 Oct 30;61(2):103304. doi: 10.1016/j.transci.2021.103304

Figure 2. Patient-reported Pain measures for those on chronic exchange transfusions (CET) compared to those not on CET.

Figure 2.

Pain measures as assessed using the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) and the Patient Reported Outcomes Measurement Information System (PROMIS), in patients with SCD on CET (black bars) compared to those not on CET (grey bars). The y-axis shows ASCQ-Me (Pain Impact, Pain Episode Frequency, Pain Episode Severity) and PROMIS (Neuropathic Pain, Nociceptive Pain) domain scores. A score of 50 is the median for the validation cohort and higher scores represent worse symptoms and lower scores represent better symptoms in all domains except in Pain Impact where lower scores represent worse symptoms and higher scores represent better symptoms. Ten is one standard deviation of the validation cohort for all domains. There were no significant differences in scores between the two groups for all measures assessed (p=>0.05).